{
  "doc_id": "CT-20189_LUMYKRAS_PIC_REEV_AvisDef_CT20189",
  "created_date": "2023",
  "country": "FR",
  "source_type": "hta_submission",
  "chunks": [
    {
      "heading": "ASSESSING HEALTH TECHNOLOGIES",
      "text": "sotorasib NOTICE ON",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "July July 2023",
      "text": "Adult Adult Sectors: reimbursement reimbursement “cancer cancer (NSCLC) systemic systemic treatment” LUMYKRAS LUMYKRAS (sotoras) therapy",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "(ISP)",
      "text": "rendered rendered (ASMR) LUMYRAS (sotorasib) to to didetaxel; limited limited by: clinical clinical relevance",
      "start_page": 1,
      "end_page": 2
    },
    {
      "heading": "Target",
      "text": "unfavorable unfavorable prognosis; this this report; ° life life results; » of of docetaxal;",
      "start_page": 2,
      "end_page": 2
    },
    {
      "heading": "patients. patients.",
      "text": "S",
      "start_page": 3,
      "end_page": 3
    },
    {
      "heading": "Contents",
      "text": "of of 15/06/20 (comparative review) sotorasib sotorasib (C01XX73) 8-tablets 8-tablets (CIP: 419 419 6) Social safety (L. L.162-17) Communities L/1223/er-LUMYKRAS er-LUMYKRAS (Sotorasib) access access (grant date 28/04/date date 07/06/2022) the the AMM: “cancer cancer (NSCBN), therapy. therapy.",
      "start_page": 3,
      "end_page": 5
    },
    {
      "heading": "Therapeutic",
      "text": "assessment assessment of: “with with date-MEDTERly”",
      "start_page": 5,
      "end_page": 5
    },
    {
      "heading": "condition condition concerned",
      "text": "tumors tumors (in in 2018). diagnoses diagnoses (70-80%) men. men.",
      "start_page": 5,
      "end_page": 6
    },
    {
      "heading": "Current support",
      "text": "BUMYMRAS_immuno-recommendation BUMYMRAS_immuno-recommendation (sotorasib), therapy therapy (including G12C).LUMYKRAS LUMYKRAS (sotorasib) of of treatment;",
      "start_page": 6,
      "end_page": 6
    },
    {
      "heading": "Drug treatments",
      "text": "Table 1: RNA RNA (NA NA cisplatin), RNA. RNA.",
      "start_page": 6,
      "end_page": 7
    },
    {
      "heading": "Immunotherapies",
      "text": "CRE CRE C/31 31 PAR",
      "start_page": 7,
      "end_page": 7
    },
    {
      "heading": "medical medical need",
      "text": "between between 15% and 50% patients. patients.",
      "start_page": 8,
      "end_page": 8
    },
    {
      "heading": "Data available",
      "text": "Phase Phase 1/2 (CodeBreak 100) CBNPC CBNPC studies; 2022. 2022.",
      "start_page": 8,
      "end_page": 8
    },
    {
      "heading": "efficacy efficacy data",
      "text": "Commission Commission (review of 15/06/2022): 100 100 (non-comparative basketball study) “outcome. outcome.” of of men/women (50%) 0 0 (30%) or 1 (70%). immunotherapy immunotherapy (or or sequentially), unless contraindicated.",
      "start_page": 8,
      "end_page": 9
    },
    {
      "heading": "Treatments received",
      "text": "randomized randomized (allocation ratio 1:1) to receive: Experimental group: sotorasib, 960 mg/day, oral; Control group: docetaxel, 75mg/IV IV (AMM dosage); following following criteria: lines lines (and and +), geographic origin (Asian vs.",
      "start_page": 9,
      "end_page": 9
    },
    {
      "heading": "Criteria for judgment",
      "text": "a a priori: 6 6 weeks; 230 230 events; survival. survival.",
      "start_page": 9,
      "end_page": 10
    },
    {
      "heading": "the the Protocol",
      "text": "of of 15/02/2021 (on on 04/06/2020), were were made: 330 330 patients; survival survival (160 events); committee. committee.",
      "start_page": 10,
      "end_page": 10
    },
    {
      "heading": "the the study",
      "text": "stage stage (MCNOC) immunoRAS immunoRAS (or or sequential). primary primary endpoint: of of 05/10/outcome outcome (O’Brien-Fleming method) weeks weeks (min-max: 0/57). the the following: pre-evaluated pre-evaluated (including a “medical endpoint” be be reevaluated); event event (a a censure) Figure Figure 1: cross-over cross-over (2-step 2-step approaches) presented. presented.",
      "start_page": 10,
      "end_page": 13
    },
    {
      "heading": "Quality of life",
      "text": "following following limitations: results. results.",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "Tolerance profile",
      "text": "weeks weeks (min-max%: 1-77). was was 28% and and 51% was was 29% and and 2% group. group.",
      "start_page": 13,
      "end_page": 14
    },
    {
      "heading": "the the PGR",
      "text": "LUMYKRAS LUMYKRAS (sotorasib) RMP (of of 15/11/2022) information. information.",
      "start_page": 14,
      "end_page": 14
    },
    {
      "heading": "Data from PBRER/PSUR",
      "text": "Report Report (PBRER)/Report Report (PSUR) from from 28/11/2021 to 27/05/period. period.",
      "start_page": 14,
      "end_page": 14
    },
    {
      "heading": "Cohort Cohort ATU",
      "text": "from from 7/06/2022 to 0/02/treatment. treatment.",
      "start_page": 14,
      "end_page": 15
    },
    {
      "heading": "Lung Lung KG12Ci",
      "text": "the the “real-life” between between 15/03/2021 and 15/04/study. study.",
      "start_page": 15,
      "end_page": 15
    },
    {
      "heading": "Curriculum",
      "text": "100 100 (NCT03600883) (960 960 mg) with with muta- systemic systemic treatment",
      "start_page": 16,
      "end_page": 16
    },
    {
      "heading": "Discussion",
      "text": "5th 5th », 6th 6th . LUMYKRAS LUMYKRAS (sotorasib) following following endpoints: is is questionable; outcome. outcome.",
      "start_page": 16,
      "end_page": 17
    },
    {
      "heading": "Transparency Transparency Commission",
      "text": "the the evaluation:",
      "start_page": 17,
      "end_page": 17
    },
    {
      "heading": "therapeutic therapeutic strategy",
      "text": "LUMYKRAS (sotorasib) cancer cancer (NSCLC) line. line.",
      "start_page": 17,
      "end_page": 17
    },
    {
      "heading": "Clinically relevant comparators",
      "text": "management management (paragraph 2.2) strategy strategy (paragraph 5.1), 2. 2.",
      "start_page": 17,
      "end_page": 17
    },
    {
      "heading": "Medical Rendering Service",
      "text": "of of non-pulmonary pulmonary disease; therapeutic-adversarial therapy-adverse disease-adaptation-prognoses-advertising prognoses-advertising prognose: Adverse outcome-efficacy-adventures. efficacy-adventures.",
      "start_page": 18,
      "end_page": 18
    },
    {
      "heading": "Medical Medical Service",
      "text": "LUMYKRAS (sotorasib) outcome outcome study; limited limited by: 1 1 month;",
      "start_page": 18,
      "end_page": 19
    },
    {
      "heading": "Target population",
      "text": "opinion. opinion.",
      "start_page": 19,
      "end_page": 19
    },
    {
      "heading": "Data request",
      "text": "Not applicable.",
      "start_page": 19,
      "end_page": 19
    },
    {
      "heading": "the the Commission",
      "text": "at at ntext; e of life; treatment. treatment.",
      "start_page": 19,
      "end_page": 19
    },
    {
      "heading": "heading heading (ISP)>",
      "text": "Row 1: Row Row 2: Adult Row 3: Sectors: City and Hospital",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "heading heading (ISP)>",
      "text": "Row 1: Recommendation of Row: Rowrepair of row: of of row:revenue of row-of of row_row2: cancer. cancer.",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "heading heading (ISP)>",
      "text": "Row 1: Row Row 2: Public Health",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "patients. patients.>",
      "text": "Row 1: Row Row 2: unfavorable unfavorable prognosis; Row 3: this this con- Row 4: text: Row 5: row row 6: life; row 7: s",
      "start_page": 2,
      "end_page": 2
    },
    {
      "heading": "heading heading Summary> (from previous page)",
      "text": "Row 1: Row Row 2: Row Row 3: Framework Row 4: DCI (ATC code) Presentations concerned*sotocrasib (L0122AM73) Row 5: Row Row 6: Row Row 7: tablets",
      "start_page": 4,
      "end_page": 4
    },
    {
      "heading": "heading heading Summary> (from previous page)",
      "text": "Row 1: DCI (ATC code) Row 2: Presentations Row 3: concerned*",
      "start_page": 4,
      "end_page": 4
    },
    {
      "heading": "heading heading Summary> (from previous page)",
      "text": "Row 1: Lists) about- Row 2: born",
      "start_page": 4,
      "end_page": 4
    },
    {
      "heading": "heading heading Summary> (from previous page)",
      "text": "Row 1: Conditions and sta- Row 2: tuts",
      "start_page": 4,
      "end_page": 4
    },
    {
      "heading": "heading heading Summary> (column column 1)",
      "text": "Row 1: Row Row 2: Row Row 3: FrameworkFragment Row 4: DCI (concernDCI concernDCI (co Row 5: Presen Row 6: concern Row 7: Lists) bornLists) Row 8: bornAMM Row 9: .Labora Row 10: Row Row 11:",
      "start_page": 4,
      "end_page": 4
    },
    {
      "heading": "heading heading Summary> (column column 2)",
      "text": "Row 1: procedure Row 2: is Row 3: Row 4: Row 5: Row Row 6: ntation Row 7: born Row 8: Row 9: conc Row 10: Row 11: Row 12: atatory Row 13: Row Row 14: r l’év Row 15: Row 16: Row 17: Row 18: Row 19: ions Row 20: Row 21:",
      "start_page": 4,
      "end_page": 4
    },
    {
      "heading": "heading heading Summary> (column column 3)",
      "text": "Row 1: educate Row 2: Row 3: Row 4: Row 5: ATC) Row 6: ns Row 7: s* Row 8: Row 9: cer- Row 10: Row 11: Row 12: e Row 13: conce Row 14: valua- Row 15: Row 16: Row 17: Row 18: Row 19: Row Row 20: Row 21:",
      "start_page": 4,
      "end_page": 4
    },
    {
      "heading": "heading heading Summary> (column column 4)",
      "text": "Row 1: alRévaluation Row 2: Row 3:",
      "start_page": 4,
      "end_page": 4
    },
    {
      "heading": "heading heading Summary> (column column 4)",
      "text": "Row 1: Row 2: Row 3:",
      "start_page": 4,
      "end_page": 4
    },
    {
      "heading": "heading heading Summary> (column column 4)",
      "text": "Row 1: sotorasib (L01XX73) Row 2: Row Row 3: Row Row 4: tablets (CIP: 3 3 6)",
      "start_page": 4,
      "end_page": 4
    },
    {
      "heading": "heading heading Summary> (column column 4)",
      "text": "Row 1: Row 2:",
      "start_page": 4,
      "end_page": 4
    },
    {
      "heading": "heading heading Summary> (column column 4)",
      "text": "Row 1: AMGEN Row 2: er- Row 3: - Row 4:",
      "start_page": 4,
      "end_page": 4
    },
    {
      "heading": "heading heading Summary> (column column 4)",
      "text": "Row 1: Initial date: 06/01/2022 (centralised procedure) Row 2: Row Row 3: Row Row 4: Row Row 5: Row Row 6: via via Row",
      "start_page": 4,
      "end_page": 4
    },
    {
      "heading": "heading heading Summary> (column column 4)",
      "text": "Row 1: a- Row 2:",
      "start_page": 4,
      "end_page": 4
    },
    {
      "heading": "condition condition concerned>",
      "text": "Row 1: RowM: Row_ Row: row_ row:row_ row: row row 3: rhc- row 4: lhcd_ lhcd_ nhc; course course of",
      "start_page": 5,
      "end_page": 5
    },
    {
      "heading": "condition condition concerned>",
      "text": "Row 1: Reminder of eva- Row 2: previous luations- Row 3: dentes",
      "start_page": 5,
      "end_page": 5
    },
    {
      "heading": "condition condition concerned>",
      "text": "Row 1: Row Row 2: Commission",
      "start_page": 5,
      "end_page": 5
    },
    {
      "heading": "heading heading Medicines>",
      "text": "Row 1: NAME (INN)Row Row 2: LaboratoryNotice",
      "start_page": 6,
      "end_page": 6
    },
    {
      "heading": "heading heading Immunotherapy>",
      "text": "Row 1: CBNPC-NA-NA Row 2: surgery surgery and/not not indicatedNA- NA Row 3: therapy therapy (NSCLC)",
      "start_page": 7,
      "end_page": 7
    },
    {
      "heading": "heading heading Immunotherapy>",
      "text": "Row 1: prior prior chemotherapy30/05/2018 (registration)Important (patients patients ALK+) Row 2: previous previous chemotherapy03/02/2016 (registration).",
      "start_page": 7,
      "end_page": 7
    },
    {
      "heading": "heading heading Immunotherapy> (column 1)",
      "text": "Row 1: CBNPC Row 2: surgery surgery and/Row Row 3: Row Row 4: with with NSCBCLC",
      "start_page": 7,
      "end_page": 7
    },
    {
      "heading": "heading heading Immunotherapy> (column 1)",
      "text": "Row 1: Row Row 2: prior prior chemotherapy",
      "start_page": 7,
      "end_page": 7
    },
    {
      "heading": "heading heading Discussion>",
      "text": "Row 1: dataRow dataRow 2: data",
      "start_page": 16,
      "end_page": 16
    },
    {
      "heading": "relevant relevant comparators>",
      "text": "Row 1: Row Row 2: the the evaluation:",
      "start_page": 17,
      "end_page": 17
    }
  ]
}